Kite Pharma, Inc.,
KITE, a clinical-stage biopharmaceutical company focused on
developing engineered autologous T cell therapy (eACT™) products for the
treatment of cancer, today announced the publication in The Lancet of clinical
results demonstrating the potential to treat relapsed or refractory acute
lymphoblastic leukemia (ALL) with an anti-CD19 chimeric antigen receptor (CAR)
T cell therapy. Kite's most advanced product candidate, KTE-C19, is an
anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T
cells to express a CAR that is designed to target CD19, a protein expressed on
the cell surface of B cell lymphomas and leukemias.
The findings from a Phase 1 clinical trial conducted by the Pediatric Oncology
Branch of the National Cancer Institute (NCI) demonstrated that administration
of anti-CD19 CAR T cells resulted in a 70% complete response rate in 20
pediatric or young adult patients with relapsed or refractory ALL. Sixty
percent of the 20 patients achieved an MRD-negative complete response. Ten of
the patients who had an MRD-negative complete response subsequently underwent
hematopoietic stem-cell transplantation (HSCT), and all 10 remained disease
free with a median follow-up of 10 months. These and other findings from the
Phase 1 study are being published in an article titled, "T cells expressing
CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children
and young adults: a phase 1 dose-escalation trial,"
http://dx.doi.org/10.1016/S0140-6736(14)61403-3, which is appearing in the
October 13, 2014 issue of The Lancet. Lead author on the article is Crystal L.
Mackall, M.D., Head of Immunology Section and Chief of the Pediatric Oncology
Branch at the National Cancer Institute.
Gary Schiller, M.D., F.A.C.P., Professor, Director, Hematological
Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine
at UCLA, commented, "This article, the first publication of an
intention-to-treat analysis from a completed clinical study of CD19-CAR
therapy in pediatric and young adult patients with relapsed/refractory ALL,
deepens our understanding of this important investigational approach. The
results show that this treatment is feasible in many patients with ALL and can
eradicate chemoresistant disease with an acceptable toxicity profile. Further,
the findings demonstrate substantially higher response rates than seen in the
literature for the most recently approved agent for refractory ALL. CD19-CAR
therapy represents a potentially important new tool to address the urgent need
for new treatment modalities in these patients."
The open-label, Phase 1 dose-escalation study enrolled patients aged 1-30
years. Prior to the study, all patients had been heavily pretreated for their
disease. Patients received a conditioning regimen of chemotherapy
(cyclophosphamide and fludarabine) followed by a single infusion of one of two
dose levels of anti-CD19-CAR T cells. The CAR-expressing T cells were produced
from each patient's own peripheral blood mononuclear cells (PBMCs), modified
using a gammaretroviral vector encoding the CAR, as well as a CD28
costimulatory moiety. After the dose-escalation phase, an expansion cohort was
treated at the maximum tolerated dose. Pursuant to the study protocol,
patients are continuing to be monitored.
As seen in other studies, infusion of anti-CD19 CAR T cells was associated
with significant, acute toxicities, including fever, hypokalemia, and
transient neurological deficits. All toxicities were fully reversible.
David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and
Development, and Chief Medical Officer, stated, "The findings of the study
reported in the Lancet further support promising results with our CD19-CAR
construct in other blood cancers, such as in patients with aggressive,
refractory non-Hodgkin's lymphoma. Toxicities were readily managed in the
Lancet study, and the findings provided important information on defining
response rates and maximum tolerated dose, as well as affirming the
feasibility of generating CD19-CAR T cells in this heavily pretreated patient
population."
Kite previously announced positive results in chemotherapy-refractory diffuse
large B-cell lymphoma (DLBCL) in a study conducted under the auspices of Kite
and the Surgery Branch of the NCI, led by Steven A. Rosenberg, M.D., Ph.D.
Kite and Dr. Rosenberg's team are collaborating under a Cooperative Research
and Development Agreement (CRADA) for the research and development of
eACT™-based product candidates for the treatment of multiple cancer
indications.
"We are greatly encouraged by the continuing strong results from the NCI using
our proprietary CD19-CAR construct in very sick patient groups," commented
Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer.
"The importance of a new approach to treating advanced cancer in the youngest
patients cannot be over-emphasized."
Dr. Belldegrun continued, "As previously reported, Kite plans to file an IND
this year to initiate a Phase 1-2 single-arm multicenter clinical trial of its
lead CD19-CAR therapy, KTE-C19, in patients with DLBCL who have failed two or
more lines of therapy. For the trial, we will manufacture product using our
streamlined and rapid production process. We are excited to advance this
promising therapy and anticipate initiating our first Kite-sponsored study
next year."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in